Enanta Pharmaceuticals, Inc.
ENTA
$13.24
-$0.26-1.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.50M | -13.09M | -11.94M | -18.70M | -18.26M |
| Total Depreciation and Amortization | 1.19M | 1.21M | 1.23M | 1.28M | 1.21M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.83M | 4.78M | 1.89M | 5.54M | 2.25M |
| Change in Net Operating Assets | 2.52M | -49.00K | -2.88M | 5.38M | 32.30M |
| Cash from Operations | -9.97M | -7.16M | -11.70M | -6.49M | 17.51M |
| Capital Expenditure | -7.00K | -15.00K | -143.00K | -1.46M | -155.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 14.01M | 11.96M | -47.16M | 3.75M | -26.33M |
| Cash from Investing | 14.01M | 11.94M | -47.30M | 2.30M | -26.48M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 49.00K | 74.89M | 51.00K | 0.00 |
| Repurchase of Common Stock | -4.31M | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.23M | -7.34M | -10.76M | -8.37M | -6.42M |
| Cash from Financing | -5.54M | -7.30M | 64.14M | -8.32M | -6.42M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.51M | -2.51M | 5.14M | -12.51M | -15.40M |